Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
To explore changes in body weight and cardiometabolic risk factors after treatment withdrawal in the STEP 1 trial extension. STEP 1 (NCT03548935) randomized 1961 adults with a body mass index ≥ 30 kg/m2 (or ≥ 27 kg/m2 with ≥ 1 weight-related co-morbidity) without diabetes to 68 weeks of once-weekly subcutaneous semaglutide 2.4 mg (including 16 weeks of dose escalation) or placebo, as an adjunct to life…
Cited by
No digest currently cites this study. It remains in the index and can be referenced from any digest.
Compounds examined
Study records state what a paper reported. PepIndex does not interpret findings, assess clinical significance, or restate results in language implying an application not present in the source. Last reviewed 23 Jul 2026.